Colorectal cancer is the second leading cause of cancer deaths in the United States.
However, this combination has been shown to produce side effects in some patients. Side effects may also result in patient hospitalization, a decrease in quality of life and even fatality. This analysis was aimed at determining associations between specific patient characteristics and the risk of developing dose-limiting side effects from the treatment regimen. The majority of these patients experienced these side effects within the first chemotherapy cycle. Age, gender, PS, and organ dysfunction were not significantly associated with a higher overall rate of dose-limiting side effects.